PolarityTE Inc.

PolarityTE — Investor Presentation (June 2019)

38 slides from PolarityTE's investor presentation, Jun 10, 2019

  1. Slide 1: PolarityTE: Where Self Regenerates Self

    PolarityTE" Where Self Regenerates Self”

  2. Slide 2: Where Self Regenerates Self

    PolarityTE™ Where Self Regenerates Self” A biotechnology company focused on transforming the lives of patients.

  3. Slide 3: Forward-Looking Statement

    @ PolarityTE” We gee Forward-Looking Statement This presentation contains forward-looking statements and projections. PolarityfE, Inc, (the "Company") makes no express or implied representation or warrant as to the completeness ofthis information or, in the case of projections, as to their attainabi

  4. Slide 4: About PolarityTE, Inc.

    About PolarityTE, Inc. + Weare a tissue focused biotechnology company that uses a patient's own cells to generate new tissue. * State of the art research facility to develop additional platform technologies (e.g., OsteoTE, CartTE) * Centralized manufacturing facility based in Salt Lake City, Utah wi

  5. Slide 5: Company History

    Company History o O ese = Om First patent application filed <Not Ce) Sa SkinTE registered with FDA 29-98-86 Lab established at Formosa fire —— Research Park First patient treated PolarityTE with SkinTE Weegee

  6. Slide 6: Minimally Polarized Functional Unit

    Minimally Polarized Functional Unit Minimally Polarized Functional Unit is best described as the smallest unit of tissue that maintains all of the complex components activated for regeneration. SS) PolarityTE” We ge

  7. Slide 7: Product Pipeline

    Product Pipeline Tissue Platforms) Optimization & Development ___ Prototype Modeling Registration Product introduction __Clinical Development Market Commercialization skin Bone cantlage Fat Skeletal Muscle Peripheral Nerve Blood Vessels Heart Muscle Liver Urogenital Gastrointestinal Lung SkinTe Oste

  8. Slide 8: Scientific Recognition...

    Scientific Recognition... + Peer Review Publication in International Wound Journal + 42 abstracts accepted for presentation at healthcare, scientific and clinical conferences around the world* = 19 abstracts accepted for podium presentations = 23abstracts accepted for poster presentations * Clinical

  9. Slide 9: Skin Components

    Skin Components SkinTE: Fully Functional, Full-Thickness Skin Epidermis Skin is much more than a single layer of cells providing a barrier—skin is the largest organ of the human body and requires regeneration of all components for normal function. a e,

  10. Slide 10: Current Treatment Options

    Current Treatment Options Scaffolds & Matrices—No Cells + Lackliving cells + Limited ability to regenerate tissue + Typically require secondary coverage with skin grafts Qn Allogeneic/Xenogeneic Cells & Tissues Risk of immune system rejection of foreign cells and tissue Can result in scarring Freque

  11. Slide 11: Split-Thickness Skin Graft Donor Sites

    Split-Thickness Skin Graft Donor Sites Split-Thickness Skin Graft Harvesting Skin Graft Donor Site After 2 Years Following Harvest BQveve

  12. Slide 12: SkinTE: The Product

    SkinTE: The Product @ Skinte * Autologous (from the patient for the patient) —_ PolantyVve + Homologous (skin for skin) + Full-thickness, functional skin + Dermis, epidermis, hypodermis, including subcutaneous fat + Appendage formation (hair, sebaceous, sweat) + Sensation, pliability The Simple Way

  13. Slide 13: SkinTE: FDA Registered Through HCT/P Pathway

    SkinTE: FDA Registered Through 361 HCT/P Pathway + Minimally manipulated * Autologous — from the patient, for the patient + Homologous ~ skin for skin + Manufacture must not involve combination with another article, except for water, crystalloids or a sterilizing, preserving or storage agents + The

  14. Slide 14: SkinTE Was Designed to Reduce Barriers and Increase Availability

    SkinTE Was Designed to Reduce Barriers and Increase Availability of Regenerative Treatments Broad Utilization: Surgeons Medical Doctors Podiatrists Physicians Assistants Nurses/Nurse Practitioners PolarityTE” Weegee Broad Applications To Date: * Acute wounds * Chronic wounds + Traumatic injuries + A

  15. Slide 15: SkinTE Regenerates Functional Skin

    SkinTE Regenerates Functional Skin SkinTE Applied to Chronic Wound on Right Lower Extremity (RLE) After Two Years of Failed Treatments ruy Before SkinTE After SkinTE Split-Thickness Skin Graft Confocal Merge SEM ster Molecular Fingerprinting of the Hair Sensation Comparing the Appendages: SkinTE Reg

  16. Slide 16: SkinTE Treats a Broad Spectrum of Wounds

    SkinTE Treats a Broad Spectrum of Wounds Diabetic Foot Ulcer Venous Leg Ulcer og as ae ae Initial Wound Initial wound Chronic Wound Acute Wound Initial wound 24 weeks after single application of SkinTE _ Initial wound 3 months after a single application of SkinTE @raive 7

  17. Slide 17: SkinTE Treats a Broad Spectrum of Wounds

    SkinTE Treats a Broad Spectrum of Wounds Traumatic Injury - Lawnmower Accident Traumatic Injury - Motor Vehicle Accident Initial wound 12 weeks after single application of SkinTE Initial wound 16 weeks after a single application of SkinTE Traumatic Injury — Motor Vehicle Accident Burn » gee z Initia

  18. Slide 18: SkinTE Treats a Broad Spectrum of Wounds

    SkinTE Treats a Broad Spectrum of Wounds Acute Burn Burn Reconstruction Initial wound 4 weeks after single application of SkinTE Post-debridement 13 months after single application of SkinTE Amputation Wound Post-Mohs Reconstruction v Pre-treatment 4 months after single application of SkinTE Initial

  19. Slide 19: Feedback from Patients, Providers and Thought-Leaders

    Feedback from Patients, Providers and Thought-Leaders “My skin is smooth. The hair is actually growing back. It doesn't itch.” sha, Burn Survivor and SkinTE Patient ind clinical appl far, | have u tial in PolarityTE” Wee ges

  20. Slide 20: Clinical Trials

    Clinical Trials Building Scientific Evidence Multicentered, Randomized Head-to-Head Trial Comparing SkinTE to Split-Thickness Skin Grafts: the Current Standard of Care Controlled Trials (RCTs) * Actively enrolling + SkinTE in the Treatment of Diabetic Foot Ulcers + Noadverse reactions to date ~ 100

  21. Slide 21: SkinTE Successfully Closing DFUs & VLUs

    SkinTE Successfully Closing DFUs & VLUs SkinTE Applied to a Diabetic Foot Ulcer SkinTE Applied to a Venous Leg Ulcer Pre-treatment 60 days after a single application of SkinTE Pre-treatment POD 47 Durability follow-up: Closed day 22 @xive -”

  22. Slide 22: Scientific Evidence

    Scientific Evidence Diabetic Foot Ulcer (DFU) Pilot Trial Results presented at the Diabetic Limb Salvage Conference and the Symposium on Advanced Wound Care + 11 DFUs (Wagner 1 and Wagner 2) that failed other therapies were treated with a single application of SkinTE + All 1 wounds demonstrated comp

  23. Slide 23: Defining the US Market

    Defining the US Market Venous Leg Ulcers (VLUs) Diabetic Foot Ulcers (DFUs) Pressure Ulcers (PUs) Prevalence Prevalence 30.3mm Prevalence ™1.2-3.0mm Estimated Number of Individuals to Prevalence of Venous Ulcers . in the United States BE Reonieinine Us win Diabetes WE Develop Pressure Ulcers Annuall

  24. Slide 24: Defining the US Market

    Defining the US Market Burns Wounds From Surgical Procedures Trauma Incidence ~1.7mm Incidence Incidence 486k ~23mm ~120-350k ar ajar Racal Number of Cardiovascular, Digestive, i | f 1) Urinary, Musculoskeletal, and Integumentary 1) Inpatient Traumatic injuries Per Year Medical Tratment (ey i5) In-P

  25. Slide 25: SkinTE Commercialization

    SkinTE Commercialization \ 2018 Limited Market Release 2019 Regional Market Release 20 ~—_— Full National Release 8,100 si 433 @ 19 Active users* In-process sites” Sales reps, 5 clinical science managers in the US” High Degree of Success with Value Analysis Committees (VAC) - average approval proces

  26. Slide 26: Reimbursement

    Reimbursement Hospital Inpatient: Outpatient Settings: Physician Office: * Bundled DRG payments * Bundled facility payments * Procedure and product payments PolarityTE” We gee 26 of 31

  27. Slide 27: OsteoTE Registered with the FDA in 2018

    Load in) OsteoTE” Registered with the FDA in 2018 Load-Displacement Biomechanical Testing iomaxillofacia

  28. Slide 28: Financial Snapshot

    Financial Snapshot * Cash, cash equivalents and short-term investments. were $447 million as of March 31, 2019 * Recent financing in April 2019 yielded an additional ~$29 million of net proceeds * Inthe three months ended March 31, 2019, cash used in operations was approximately $5.5 million per mon

  29. Slide 29: Management Team

    David Seaburg President of Corporate Development Cowen and Company Stephen Milner, MD, DDS, DSc, FACS Chief Clinical Officer Johns Hopkins Hospital & Schoo! ‘of Medicine Mark Lehman, J.D. Chief Legal Officer Parsons Behe & Latimer Jennifer Burdman, JD Chief Intellectual Property Officer & Deputy Gen

  30. Slide 30: Board of Directors

    Board of Directors Peter Cohen, MBA Lead Director + Former Board Member ofthe NYSE + Former Chairman and CEO of Shestson Lehman Brothers + Former Chain and CEO of Cowen ne. + Vice Chairman and Lad Director ofthe Board of Directors of Scenic Gomes Corporation + Feder Reserelntemational Capital Market

  31. Slide 31: Welcome to the Shift

    Welcome to the Shift PolarityTE® Corporate PolarityTE® Investors Relations ae www PolarityTEcom Rich Haerle, MBA, MPH ParadigmShift@PolarityTE.com VP of investor Relations Corporate Inquiries: (800) 378-2694 IR Inquiries: (385) 237-5786 Corporatelnquiries@PolartyTEcom IR@PolarityTE.com Nasdaq; PTE S

  32. Slide 32: Appendix

    Appendix 9% ——e

  33. Slide 33: Innovation: RTD and ARC Pipelines

    Innovation: RTD and ARC Pipelines Related Technology Derivatives (RID) Programs Program Optimization & Development Prototype Modeling Clinical Development Market Commercialization Ho-Accearant & Mecuistion Composite Tesua Systm Advanced CaliTissue Devices Advanced Partides Advanced Fibers Advanced R

  34. Slide 34: The Process: Standard of Care vs. SkinTE

    The Process: Standard of Care vs. SkinTE Current Standard of Care wnt Split-Thickness Skin Graft Healing Autologous Homologous Skin Construct Healing PolarityTE” We gee

  35. Slide 35: Where Skin Grafts Fail

    Where Skin Grafts Fail SkinTE Following Replacement of Split-Thickness Skin Graft in Fibrotic Wound Bed Excision of skin graft 2weeks p 4 Weeks Post-Op este Conducting pinch test of SkinTE at 6 months Punch biopsy of SkinTE- regenerated skin depicts al layers of full-thickness skin and appendages Re

  36. Slide 36: Chronic Wound

    Chronic Wound SkinTE Applied to Chronic Wound on Right Lower Extremity (RLE) After Two Years of Failed Treatments u Ii ) t | Y yj year-old chronic refractory wound on right lower extremity Right lower extremity 2year-old previously 12 weeks after single placed skin graft on left application of SkinT

  37. Slide 37: Patient Experience

    Patient Experience “If |had to choose between SkinTE and another skin graft, | would choose SkinTE every time, because it is actually working, and you do not have a huge area of healthy skin removed that also then needs to heal, like with traditional skin grafts.” —Devon, a SkinTE Patient

  38. Slide 38: Poster #CS-03

    Poster #CS-03 Closure of refractory diabetic foot ulcers and venous stasis leg ulcers using a single application of an autologous homologous skin construct in the clinic setting David G. Armstrong', Dennis Orgill’, Robert Galiano‘, Paul Glat’, Charles M. Zelen® 1 Sotwesr Acai anh Saag lune (SALSA}.

PolarityTE — Investor Presentation (June 2019) on 6ix